Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ciafaloni, E.
Right arrow Articles by Sanders, D. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ciafaloni, E.
Right arrow Articles by Sanders, D. B.
Neurology 2000;55:448-450
© 2000 American Academy of Neurology
Brief Communications

Retrospective analysis of the use of cyclosporine in myasthenia gravis

Emma Ciafaloni, MD, Nirjaleshwar K. Nikhar, MD, MRCP, Janice M. Massey, MD and Donald B. Sanders, MD

From the Department of Medicine, Division of Neurology, Duke University Medical Center, Durham, NC.

Address correspondence and reprint requests to Dr. Donald B. Sanders, Duke University Medical Center, DUMC 3403, Durham, NC 27710.

The authors reviewed the records of patients with myasthenia gravis who took cyclosporine for at least 6 months between November 1987 and January 1999. Of 57 patients who took cyclosporine for an average of 3.5 years, 55 (96%) had clinical improvement. The median time to best clinical response was 7 months. Corticosteroids were discontinued or decreased in 95% of 38 patients taking them. Major side effects included elevated serum creatinine (28%) and malignancy (11%). Five percent could not afford or tolerate the drug.




This article has been cited by other articles:


Home page
 PNHome page
D Hilton-Jones
When the patient fails to respond to treatment: myasthenia gravis
Practical Neurology, November 1, 2007; 7(6): 405 - 411.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
T Konishi, Y Yoshiyama, M Takamori, T Saida, and the Japanese FK506 MG Study Group
Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus)
J. Neurol. Neurosurg. Psychiatry, March 1, 2005; 76(3): 448 - 450.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
E Ciafaloni
Mycophenolate mofetil and myasthenia gravis
Lupus, March 1, 2005; 14(3_suppl): s46 - s49.
[Abstract] [PDF]

Home page
 LupusHome page
E. Ciafaloni
Mycophenolate mofetil and myasthenia gravis
Lupus, January 1, 2005; 14(1_suppl): s46 - s49.
[Abstract] [PDF]

Home page
 NeurologyHome page
M.N. Meriggioli, E. Ciafaloni, K.A. Al-Hayk, J. Rowin, B. Tucker-Lipscomb, J.M. Massey, and D.B. Sanders
Mycophenolate mofetil for myasthenia gravis: An analysis of efficacy, safety, and tolerability
Neurology, November 25, 2003; 61(10): 1438 - 1440.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by AAN Enterprises, Inc.